GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (FRA:5JA1) » Definitions » Debt-to-Asset

Sprint Bioscience AB (FRA:5JA1) Debt-to-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sprint Bioscience AB Debt-to-Asset?

Sprint Bioscience AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Sprint Bioscience AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Sprint Bioscience AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €4.05 Mil. Sprint Bioscience AB's debt to asset for the quarter that ended in Sep. 2024 was 0.00.


Sprint Bioscience AB Debt-to-Asset Historical Data

The historical data trend for Sprint Bioscience AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB Debt-to-Asset Chart

Sprint Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.30 - - -

Sprint Bioscience AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sprint Bioscience AB's Debt-to-Asset

For the Biotechnology subindustry, Sprint Bioscience AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Debt-to-Asset falls into.



Sprint Bioscience AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sprint Bioscience AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Sprint Bioscience AB's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sprint Bioscience AB  (FRA:5JA1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Sprint Bioscience AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB Headlines

No Headlines